Generics North America (NAFTA) Industry Guide 2015-2024
Generics North America (NAFTA) Industry Guide 2015-2024
SUMMARY
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $120,739.0 million in 2019.The Mexico was the fastest growing country, with a CAGR of 9.9% over the 2015-19 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $108,922.3 million in 2019. This was followed by Mexico and Canada, with a value of $6,634.9 and $5,181.8 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $118,075.6 million in 2024, followed by Mexico and Canada with expected values of $8,408.8 and $5,964.1 million, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
- What was the size of the NAFTA generics market by value in 2019?
- What will be the size of the NAFTA generics market in 2024?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?
1 INTRODUCTION
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 GENERICS IN MEXICO
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 GENERICS IN THE UNITED STATES
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 COMPANY PROFILES
6.1. Pfizer Inc.
6.2. Teva Pharmaceutical Industries Limited
6.3. Apotex, Inc.
6.4. Mylan N.V.
6.5. Sun Pharmaceutical Industries Ltd
7 APPENDIX
7.1. Methodology
7.2. About MarketLine
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 GENERICS IN MEXICO
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 GENERICS IN THE UNITED STATES
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 COMPANY PROFILES
6.1. Pfizer Inc.
6.2. Teva Pharmaceutical Industries Limited
6.3. Apotex, Inc.
6.4. Mylan N.V.
6.5. Sun Pharmaceutical Industries Ltd
7 APPENDIX
7.1. Methodology
7.2. About MarketLine
LIST OF TABLES
Table 1: NAFTA countries generics industry, revenue ($m), 2015-24
Table 2: NAFTA countries generics industry, revenue ($m), 2015-19
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2019-24
Table 4: Canada generics market value: $ million, 2015–19
Table 5: Canada generics market volume: % of total pharma, 2015–19
Table 6: Canada generics market geography segmentation: $ million, 2019
Table 7: Canada generics market value forecast: $ million, 2019–24
Table 8: Canada generics market volume forecast: % of total pharma, 2019–24
Table 9: Canada size of population (million), 2015–19
Table 10: Canada gdp (constant 2005 prices, $ billion), 2015–19
Table 11: Canada gdp (current prices, $ billion), 2015–19
Table 12: Canada inflation, 2015–19
Table 13: Canada consumer price index (absolute), 2015–19
Table 14: Canada exchange rate, 2015–19
Table 15: Mexico generics market value: $ million, 2015–19
Table 16: Mexico generics market volume: % of total pharma, 2015–19
Table 17: Mexico generics market geography segmentation: $ million, 2019
Table 18: Mexico generics market value forecast: $ million, 2019–24
Table 19: Mexico generics market volume forecast: % of total pharma, 2019–24
Table 20: Mexico size of population (million), 2015–19
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2015–19
Table 22: Mexico gdp (current prices, $ billion), 2015–19
Table 23: Mexico inflation, 2015–19
Table 24: Mexico consumer price index (absolute), 2015–19
Table 25: Mexico exchange rate, 2015–19
Table 26: United States generics market value: $ billion, 2015–19
Table 27: United States generics market volume: % of total pharma, 2015–19
Table 28: United States generics market geography segmentation: $ billion, 2019
Table 29: United States generics market value forecast: $ billion, 2019–24
Table 30: United States generics market volume forecast: % of total pharma, 2019–24
Table 31: United States size of population (million), 2015–19
Table 32: United States gdp (constant 2005 prices, $ billion), 2015–19
Table 33: United States gdp (current prices, $ billion), 2015–19
Table 34: United States inflation, 2015–19
Table 35: United States consumer price index (absolute), 2015–19
Table 36: United States exchange rate, 2015–19
Table 37: Pfizer Inc.: key facts
Table 38: Pfizer Inc.: Annual Financial Ratios
Table 39: Pfizer Inc.: Key Employees
Table 40: Pfizer Inc.: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Apotex, Inc.: key facts
Table 45: Apotex, Inc.: Key Employees
Table 46: Mylan N.V.: key facts
Table 47: Mylan N.V.: Annual Financial Ratios
Table 48: Mylan N.V.: Key Employees
Table 49: Sun Pharmaceutical Industries Ltd: key facts
Table 50: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 1: NAFTA countries generics industry, revenue ($m), 2015-24
Table 2: NAFTA countries generics industry, revenue ($m), 2015-19
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2019-24
Table 4: Canada generics market value: $ million, 2015–19
Table 5: Canada generics market volume: % of total pharma, 2015–19
Table 6: Canada generics market geography segmentation: $ million, 2019
Table 7: Canada generics market value forecast: $ million, 2019–24
Table 8: Canada generics market volume forecast: % of total pharma, 2019–24
Table 9: Canada size of population (million), 2015–19
Table 10: Canada gdp (constant 2005 prices, $ billion), 2015–19
Table 11: Canada gdp (current prices, $ billion), 2015–19
Table 12: Canada inflation, 2015–19
Table 13: Canada consumer price index (absolute), 2015–19
Table 14: Canada exchange rate, 2015–19
Table 15: Mexico generics market value: $ million, 2015–19
Table 16: Mexico generics market volume: % of total pharma, 2015–19
Table 17: Mexico generics market geography segmentation: $ million, 2019
Table 18: Mexico generics market value forecast: $ million, 2019–24
Table 19: Mexico generics market volume forecast: % of total pharma, 2019–24
Table 20: Mexico size of population (million), 2015–19
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2015–19
Table 22: Mexico gdp (current prices, $ billion), 2015–19
Table 23: Mexico inflation, 2015–19
Table 24: Mexico consumer price index (absolute), 2015–19
Table 25: Mexico exchange rate, 2015–19
Table 26: United States generics market value: $ billion, 2015–19
Table 27: United States generics market volume: % of total pharma, 2015–19
Table 28: United States generics market geography segmentation: $ billion, 2019
Table 29: United States generics market value forecast: $ billion, 2019–24
Table 30: United States generics market volume forecast: % of total pharma, 2019–24
Table 31: United States size of population (million), 2015–19
Table 32: United States gdp (constant 2005 prices, $ billion), 2015–19
Table 33: United States gdp (current prices, $ billion), 2015–19
Table 34: United States inflation, 2015–19
Table 35: United States consumer price index (absolute), 2015–19
Table 36: United States exchange rate, 2015–19
Table 37: Pfizer Inc.: key facts
Table 38: Pfizer Inc.: Annual Financial Ratios
Table 39: Pfizer Inc.: Key Employees
Table 40: Pfizer Inc.: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Apotex, Inc.: key facts
Table 45: Apotex, Inc.: Key Employees
Table 46: Mylan N.V.: key facts
Table 47: Mylan N.V.: Annual Financial Ratios
Table 48: Mylan N.V.: Key Employees
Table 49: Sun Pharmaceutical Industries Ltd: key facts
Table 50: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
LIST OF FIGURES
Figure 1: NAFTA countries generics industry, revenue ($m), 2015-24
Figure 2: NAFTA countries generics industry, revenue ($m), 2015-19
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2019-24
Figure 4: Canada generics market value: $ million, 2015–19
Figure 5: Canada generics market volume: % of total pharma, 2015–19
Figure 6: Canada generics market geography segmentation: % share, by value, 2019
Figure 7: Canada generics market value forecast: $ million, 2019–24
Figure 8: Canada generics market volume forecast: % of total pharma, 2019–24
Figure 9: Forces driving competition in the generics market in Canada, 2019
Figure 10: Drivers of buyer power in the generics market in Canada, 2019
Figure 11: Drivers of supplier power in the generics market in Canada, 2019
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2019
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2019
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2019
Figure 15: Mexico generics market value: $ million, 2015–19
Figure 16: Mexico generics market volume: % of total pharma, 2015–19
Figure 17: Mexico generics market geography segmentation: % share, by value, 2019
Figure 18: Mexico generics market value forecast: $ million, 2019–24
Figure 19: Mexico generics market volume forecast: % of total pharma, 2019–24
Figure 20: Forces driving competition in the generics market in Mexico, 2019
Figure 21: Drivers of buyer power in the generics market in Mexico, 2019
Figure 22: Drivers of supplier power in the generics market in Mexico, 2019
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2019
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2019
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2019
Figure 26: United States generics market value: $ billion, 2015–19
Figure 27: United States generics market volume: % of total pharma, 2015–19
Figure 28: United States generics market geography segmentation: % share, by value, 2019
Figure 29: United States generics market value forecast: $ billion, 2019–24
Figure 30: United States generics market volume forecast: % of total pharma, 2019–24
Figure 31: Forces driving competition in the generics market in the United States, 2019
Figure 32: Drivers of buyer power in the generics market in the United States, 2019
Figure 33: Drivers of supplier power in the generics market in the United States, 2019
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2019
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2019
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2019
Figure 1: NAFTA countries generics industry, revenue ($m), 2015-24
Figure 2: NAFTA countries generics industry, revenue ($m), 2015-19
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2019-24
Figure 4: Canada generics market value: $ million, 2015–19
Figure 5: Canada generics market volume: % of total pharma, 2015–19
Figure 6: Canada generics market geography segmentation: % share, by value, 2019
Figure 7: Canada generics market value forecast: $ million, 2019–24
Figure 8: Canada generics market volume forecast: % of total pharma, 2019–24
Figure 9: Forces driving competition in the generics market in Canada, 2019
Figure 10: Drivers of buyer power in the generics market in Canada, 2019
Figure 11: Drivers of supplier power in the generics market in Canada, 2019
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2019
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2019
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2019
Figure 15: Mexico generics market value: $ million, 2015–19
Figure 16: Mexico generics market volume: % of total pharma, 2015–19
Figure 17: Mexico generics market geography segmentation: % share, by value, 2019
Figure 18: Mexico generics market value forecast: $ million, 2019–24
Figure 19: Mexico generics market volume forecast: % of total pharma, 2019–24
Figure 20: Forces driving competition in the generics market in Mexico, 2019
Figure 21: Drivers of buyer power in the generics market in Mexico, 2019
Figure 22: Drivers of supplier power in the generics market in Mexico, 2019
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2019
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2019
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2019
Figure 26: United States generics market value: $ billion, 2015–19
Figure 27: United States generics market volume: % of total pharma, 2015–19
Figure 28: United States generics market geography segmentation: % share, by value, 2019
Figure 29: United States generics market value forecast: $ billion, 2019–24
Figure 30: United States generics market volume forecast: % of total pharma, 2019–24
Figure 31: Forces driving competition in the generics market in the United States, 2019
Figure 32: Drivers of buyer power in the generics market in the United States, 2019
Figure 33: Drivers of supplier power in the generics market in the United States, 2019
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2019
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2019
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2019
